Fermenta Biotech Ltd

Fermenta Biotech Ltd announced the voting results of its 74th Annual General Meeting (AGM) held on August 11, 2026. All resolutions presented to the shareholders, including the adoption of financial statements, declaration of dividend, appointment of a director, and approval of related party transactions, received overwhelming support. The voting was conducted through remote e-voting and electronic voting at the AGM, with a scrutineer appointed to oversee the process. The results indicate strong shareholder confidence in the company's management and financial performance.

Fermenta Biotech Ltd presented its performance at its 74th Annual General Meeting, highlighting a year of "operating momentum, renewed strategic conviction, and capital commitment." The company reported a record consolidated revenue of ₹548 crore for FY26, a 14% increase from FY25's ₹481 crore. Core EBITDA, excluding real estate, surged 44% to ₹120 crore, with a Profit After Tax (PAT) of ₹70 crore. Key achievements include the grant of a plant-source Vitamin D3 process patent, EDQM CEP for D3 100 SD, and approval for ₹110 crore in new Dahej capacity. The company also noted ten consecutive quarters of positive results across its three operating businesses, emphasizing innovation, scale, and focus in its strategy.

Fermenta Biotech Ltd reported unaudited Q1FY27 consolidated revenue of INR 126.2 crore, flat quarter-on-quarter (QoQ) and down 13% year-on-year (YoY). EBITDA stood at INR 22.4 crore, down 39% YoY and 11% QoQ. Profit After Tax (PAT) declined significantly by 56% YoY to INR 9.5 crore, impacted by non-recurring items in the previous year's comparable quarter. Human nutrition volumes saw an 18% QoQ increase, and the Indian market's contribution rose to 47% of consolidated revenue. The company highlighted growth in Other APIs and Intermediates, and Green Chemistry Solutions/Enzymes.

Fermenta Biotech Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results on August 11, 2026. The company also submitted the Limited Review Reports from M/s. SRBC & Co. LLP, Chartered Accountants, who provided an unmodified opinion on the financial results.

Fermenta Biotech Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results. The company also submitted the Limited Review Reports from its statutory auditors, M/s. SRBC & Co. LLP, who provided an unmodified opinion. The Board meeting took place on August 11, 2026.

Fermenta Biotech Limited announced the successful listing of its 2,94,30,987 equity shares on the National Stock Exchange of India Limited (NSE) effective August 4, 2026. The shares will trade under the symbol FERMENTA and ISIN INE225B01021. This dual listing on both NSE and BSE (where it has been listed since 1977 under Scrip Code 506414) aims to increase accessibility for a wider investor community, enhance visibility, and facilitate more efficient price discovery. The company, a leading manufacturer of Vitamin D3 API and other nutritional ingredients, views this as a significant milestone in its 75-year journey, reflecting its growth and expanding global customer base.

Fermenta Biotech Limited announced that its existing 2,94,30,987 equity shares will be listed and admitted for trading on the National Stock Exchange of India Limited (NSE) effective August 4, 2026. The company's symbol on NSE will be 'FERMENTA'. This listing follows NSE's approval and is in compliance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The shares will be of Rs. 5/- each, fully paid up, with distinctive numbers ranging from 1 to 29430987. The market lot is set at 1, and there are no lock-in details applicable. This move expands the company's accessibility to a wider investor base on a major stock exchange.

Fermenta Biotech Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. The report, which forms part of the Annual Report, is available on the company's website. Fermenta emphasizes that responsible business practices and sustainability are core to its work ethics and governance, aligning with environmental, social, and governance norms. The company's primary business activity is the manufacturing of Active Pharmaceutical Ingredients, Aqua CHL, Biotechnology, and Nutraceutical products, accounting for 96.4% of its turnover. Key products include Vitamin D3, with exports contributing 58% of the total turnover. The report details operational locations, markets served, employee statistics, and commitments to responsible business conduct.

Fermenta Biotech Limited has issued a notice for its 74th Annual General Meeting (AGM) scheduled for August 11, 2026, at 3:00 p.m. IST, to be conducted via Video Conferencing/Other Audio-Visual Means. The agenda includes the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026. A dividend of ₹3.75 per equity share is proposed. Key resolutions also involve the re-appointment of Ms. Rajeshwari Datla as a director, approval for her continuation as a Non-Executive Director given her age, ratification of the Cost Auditor's remuneration for FY27, and approval for material related party transactions. The notice is being sent to shareholders via email or through web-links for the Annual Report.

Fermenta Biotech Ltd has submitted its Annual Report for the financial year 2025-26, along with the notice for its 74th Annual General Meeting (AGM). The AGM is scheduled for Tuesday, August 11, 2026, at 3:00 p.m. IST. The report highlights the company's operating momentum, strategic conviction, and capital commitment, emphasizing its role in providing high-standard, science-backed nutritional ingredients. Fermenta leverages its expertise in process, molecular science, and green chemistry to serve global customers across pharmaceutical, dietary supplement, food and beverage, and animal nutrition sectors. The report details the company's innovation in APIs, intermediates, and environmental solutions, supported by global manufacturing and R&D capabilities. It also touches upon strategic alliances, international certifications, and a strong focus on research and development.